Aeglea BioTherapeutics, Inc. 4
4 · Aeglea BioTherapeutics, Inc. · Filed Apr 12, 2016
Insider Transaction Report
Form 4
Rowlinson Scott W
VP, Research
Transactions
- Conversion
Common Stock
2016-04-12+11,204→ 11,204 total(indirect: By Trust) - Conversion
Series B Preferred Stock
2016-04-12−11,204→ 0 total(indirect: By Trust)Exercise: $0.00→ Common Stock (11,204 underlying)
Holdings
- 16,749
Common Stock
Footnotes (2)
- [F1]In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.
- [F2]The Reporting Person serves as a co-trustee.